Patrick M. Schlievert

Hennepin Life Sciences LLC operates as a clinical-stage biotechnology company which focuses on identifying and developing antimicrobial therapeutics. It is advancing its novel antimicrobial, GML Gel, for local administration to prevent and treat CA-UTIs caused by ESKAPE pathogens in hospitals and long-term care centers. The company was founded by Patrick M. Schlievert, William Merrill Faulkner and Douglas Wicks in 2009 and is headquartered in Plymouth, MN.

ImmuVen, Inc. develops drugs to treat viral diseases and cancer. The firm develops biotherapeutics to treat cancer, infectious disease, and autoimmune disorders. It’s platform allows rapid selection and optimization of T cell receptors with high affinity to targets in cancer, infections, and autoimmune pathways. The company was founded by David Kranz and Patrick M Schlievert in November 2008 and is headquartered in Champaign, IL.